ModifiedCignaPolicy N/A

Wakefulness-Promoting Agents (armodafinil, modafinil) - Prior Authorization with Step Therapy

Prior authorization with step therapy requirements for coverage of modafinil and armodafinil (brand and generic) for adults across specified indications; applies to Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyWakefulness-Promoting Agents (armodafinil, modafinil) - Prior Authorization with Step Therapy

Policy CodePolicy N/A

Change TypeMaterial revisions to PA criteria, specialist and diagnostic requirements, and brand exception

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization and document trial of generic modafinil/armodafinil; for brand requests include prescriber rationale that an inactive-ingredient difference would cause significant allergy or serious adverse reaction.

SourceLink

POLICY UPDATE CHANGES

For Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea the requirement was changed from 'use in conjunction with continuous positive airway pressure or patient is unable to initiate or tolerate continuous positive airway pressure' to 'use in conjunction with positive airway pressure or patient is unable to initiate or tolerate positive airway pressure', and a note clarified that positive airway pressure can include CPAP, APAP, or BPAP.

Specialist prescribing/consultation requirement clarified: for certain indications approval requires prescription by or consultation with a physician who specializes in the condition; idiopathic hypersomnia diagnostic criteria were detailed to require PSG and MSLT and congruent results, and specialist criterion revised to 'sleep specialist or neurologist'.

Brand Provigil or Nuvigil may be requested only if patient tried generic and brand is needed due to inactive ingredient differences causing significant allergy or serious adverse reaction.

The phrase '/Hypopnea Syndrome' was removed from the approval condition for Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Medical Necessity

Initial FDA-Approved Indications

Covered when ALL of the following are met (for each indication as specified):

Narcolepsy (Excessive Daytime Sleepiness): Approve for 1 year if A) Patient is ≥ 18 years of age; AND B) Patient has been evaluated using polysomnography and a multiple sleep latency test; AND C) According to the prescriber, diagnosis of narcolepsy has been confirmed; AND D) The medication is prescribed by or in consultation with a sleep specialist physician or a neurologist; AND E) If brand Provigil or Nuvigil is being requested, the patient meets BOTH of the following: i. Patient has tried generic modafinil or generic armodafinil; AND ii. Brand product is being requested due to a formulation difference in the inactive ingredient(s) which, per the prescriber, would result in a significant allergy or serious adverse reaction.

From policy FDA-Approved Indications section.

Obstructive Sleep Apnea (Excessive Daytime Sleepiness): Approve for 1 year if A) Patient is ≥ 18 years of age; AND B) Patient meets ONE of the following: i. Armodafinil/modafinil will be used in conjunction with positive airway pressure therapy; OR ii. Patient is unable to initiate or tolerate positive airway pressure therapy; AND C) If brand Provigil or Nuvigil is being requested, the patient meets BOTH of the following: i. Patient has tried generic modafinil or generic armodafinil; AND ii. Brand product is being requested due to a formulation difference in the inactive ingredient(s) which, per the prescriber, would result in a significant allergy or serious adverse reaction.

Positive airway pressure can include CPAP, APAP, or BPAP.

Shift Work Sleep Disorder (Excessive Sleepiness): Approve for 1 year if A) Patient is ≥ 18 years of age; AND B) Patient works at least five overnight shifts per month; AND C) If brand Provigil or Nuvigil is being requested, the patient meets BOTH of the following: i. Patient has tried generic modafinil or generic armodafinil; AND ii. Brand product is being requested due to a formulation difference in the inactive ingredient(s) which, per the prescriber, would result in a significant allergy or serious adverse reaction.

From policy FDA-Approved Indications section.

Other Indications with Supportive Evidence

Covered when ALL of the following are met (per specific indication):

Adjunctive/Augmentation Treatment for Depression in Adults: Approve for 1 year if A) Patient is ≥ 18 years of age; AND B) Patient is concurrently receiving other medication therapy for depression (e.g., SSRI or SNRI); AND C) If brand Provigil or Nuvigil is being requested, the patient meets BOTH of the following: i. Patient has tried generic modafinil or generic armodafinil; AND ii. Brand product is being requested due to a formulation difference in the inactive ingredient(s) which, per the prescriber, would result in a significant allergy or serious adverse reaction.

Examples of other medications include SSRIs and SNRIs.

Excessive Daytime Sleepiness Associated with Myotonic Dystrophy: Approve for 1 year if A) Patient is ≥ 18 years of age; AND B) If brand Provigil or Nuvigil is being requested, the patient meets BOTH of the following: i. Patient has tried generic modafinil or generic armodafinil; AND ii. Brand product is being requested due to a formulation difference in the inactive ingredient(s) which, per the prescriber, would result in a significant allergy or serious adverse reaction.

From Other Uses with Supportive Evidence section.

Excessive Daytime Sleepiness Associated with Parkinson's Disease:

Not Medically Necessary / Not Covered

Modafinil and armodafinil are considered not medically necessary for the following uses:

Not covered indications: 1. Attention Deficit Hyperactivity Disorder (ADHD); 2. Bipolar Disorder, including bipolar depression; 3. Cancer-Related Fatigue; 4. Chronic Fatigue Syndrome; 5. Excessive Daytime Sleepiness Associated with Primary Insomnia; 6. Enhancement of Performance in Situations of Induced Sleep Deprivation (general population); 7. Fibromyalgia; 8. Hypersomnia, fatigue or sleepiness due to other conditions (not idiopathic hypersomnia); 9. Post-stroke sleep-wake disorders or sleep disorders; and other off-label uses without sufficient evidence.

List may not be exhaustive; policy will be updated as new data are available.

Other Uses with Supportive Evidence — Brand exception

Brand Provigil or Nuvigil requests are supported when ALL of the following are met:

Brand exception: i. Patient has tried generic modafinil or generic armodafinil; AND ii. Brand product (Nuvigil or Provigil) is being requested due to a formulation difference in the inactive ingredient(s) which, per the prescriber, would result in a significant allergy or serious adverse reaction.

Applies to Provigil or Nuvigil brand requests.

The products Nuvigil (armodafinil) and Provigil (modafinil) are considered not medically necessary for any other uses that are not specifically listed as covered in this policy. Requests for indications outside the approved or supported uses may be denied as not covered.

Nuvigil (armodafinil) and Provigil (modafinil) are considered not medically necessary for any other uses not explicitly supported by this policy. Coverage is limited to the indications and conditions detailed in the covered indications sections.

Use of these agents is considered not medically necessary for uses other than those specified in this policy. Providers should not expect coverage for off‑label or unlisted indications unless the submission meets the policy’s specified criteria.

The policy explicitly lists specific conditions for which modafinil and armodafinil are not medically necessary. Examples include: Attention Deficit Hyperactivity Disorder (ADHD); Bipolar Disorder (including bipolar depression); Cancer‑Related Fatigue; Chronic Fatigue Syndrome; Excessive Daytime Sleepiness Associated with Primary Insomnia; Enhancement of Performance in Situations of Induced Sleep Deprivation; Fibromyalgia; Hypersomnia, fatigue or sleepiness due to other conditions (not idiopathic hypersomnia); and Post‑stroke sleep‑wake disorders or sleep disorders. This list may not be exhaustive and will be updated as new evidence becomes available.

Product and Diagnostic Coding

Referenced productsmixed

Nuvigil / Provigil

Brand products: Nuvigil (armodafinil) and Provigil (modafinil) as referenced in policy header

MSLT mean sleep latency — < 8 minutes

MSLT thresholdMean sleep latency < 8 minutes on the five naps

Test contextPerformed the day after overnight polysomnography (PSG)

PurposeAssesses daytime sleepiness by measuring how quickly a person falls asleep

Clinical implicationMean < 8 minutes indicates excessive daytime sleepiness

Sleep-onset REM episodes for narcolepsy

Diagnostic criterionREM sleep occurring within 15 minutes on at least 2 of the five MSLT naps and the overnight study

Prior Authorization, Step Therapy, and Provider Documentation

Prior Authorization

Prior Authorization with Step Therapy

Prior authorization is required for modafinil and armodafinil (brand and generic) for prescription benefit coverage. For specified indications approval requires prescription by or consultation with a specialist (e.g., sleep specialist or neurologist) when noted in the criteria. Step therapy is in effect: when clinically appropriate, the patient must try one Step 1 product (generic modafinil or generic armodafinil) prior to consideration of brand Provigil or Nuvigil. Approvals are time-limited as specified in the coverage criteria.

Prior authorization required for brand and generic modafinil/armodafinil
Specialist prescriber or consultation may be required for certain indications
Step therapy (generic-first) applies before brand Provigil/Nuvigil

Prior Authorization

Prior authorization and brand exception

If a brand product (Provigil or Nuvigil) is requested, a prior trial of the corresponding generic (modafinil or armodafinil) is required unless the prescriber documents that the brand is needed because of a formulation difference in inactive ingredients that would cause a significant allergy or serious adverse reaction. Brand exception requests must include documentation of the generic trial and the clinical rationale for the brand override.

Background and Scope

Armodafinil and modafinil are wake‑promoting agents indicated to improve wakefulness in adults with narcolepsy, in adults with excessive daytime sleepiness associated with obstructive sleep apnea (as adjunctive therapy or when patients are unable to initiate or tolerate positive airway pressure), and for shift work sleep disorder. They are categorized as Schedule IV controlled substances, and diagnosis of narcolepsy or idiopathic hypersomnia often requires supportive testing such as an overnight polysomnogram (PSG) and a multiple sleep latency test (MSLT). Prior authorization with step therapy is required for these medications; approvals for covered indications are granted when the policy’s clinical criteria and documentation requirements are met.

Definitions and Diagnostic Criteria

Polysomnogram (PSG) — definition and role in diagnosis

DefinitionPolysomnogram (PSG) is an overnight recording of brain and muscle activity, breathing, and eye movements used to diagnose narcolepsy and other sleep disorders

Role in diagnosisRequired, along with MSLT, to establish a diagnosis of narcolepsy

TimingPSG is performed the night before the MSLT

Data collectedRecords brain and muscle activity, respiratory parameters, and eye movements

Multiple sleep latency test (MSLT)

DefinitionMultiple sleep latency test (MSLT): a daytime test of sleepiness consisting of five short naps separated by 2 hours

Policy Revision History

2026-02-11material_revisionLatest

Policy selected revision applied (see history) reflecting material updates to specialist requirements and diagnostic documentation for idiopathic hypersomnia and other indications.

2025-10-15terminology_change

Removed the phrase '/Hypopnea Syndrome' from the approval condition for Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea.

2025-09-03operational_wording_change

Policy Summary

PayerCigna

PolicyWakefulness-Promoting Agents (armodafinil, modafinil) - Prior Authorization with Step Therapy

Policy CodePolicy N/A

Change TypeMaterial revisions to PA criteria, specialist and diagnostic requirements, and brand exception

Effective DateN/A

Next Review DateN/A

SourceLink

On This Page

Idiopathic Hypersomnia: Approve for 1 year if A) Patient is ≥ 18 years of age; AND B) Patient has been evaluated using polysomnography and a multiple sleep latency test; AND C) According to the prescriber, results of the polysomnography and multiple sleep latency test are congruent with a diagnosis of idiopathic hypersomnia; AND D) The medication has been prescribed by or in consultation with a sleep specialist or a neurologist; AND E) If brand Provigil or Nuvigil is being requested, the patient meets BOTH of the following: i. Patient has tried generic modafinil or generic armodafinil; AND ii. Brand product is being requested due to a formulation difference in the inactive ingredient(s) which, per the prescriber, would result in a significant allergy or serious adverse reaction.

Diagnostic testing (PSG and MSLT) and specialist involvement required.

Documentation Required

Required clinical documentation

For covered indications the prescriber must provide specific clinical documentation to support medical necessity. Documentation should include age, relevant diagnostic testing results (e.g., polysomnography and multiple sleep latency test when required), confirmation of diagnosis by the prescriber, and evidence of specialist involvement or consultation when the criteria require it. For brand exception requests include documentation of prior generic trial and rationale for brand use.

Age of the patient (e.g., ≥ 18 years where specified)
Diagnostic testing as required (polysomnography, MSLT) and results congruent with diagnosis when indicated
Prescriber-confirmed diagnosis and note if prescribed by or in consultation with required specialist
For brand requests: documentation of prior generic trial and prescriber-justified reason for brand

Denial Risk

Denial triggers — Not medically necessary indications

Requests for modafinil or armodafinil for indications not listed as covered or supported by evidence are considered not medically necessary and may be denied. Examples of not medically necessary uses include ADHD, bipolar disorder (including bipolar depression), cancer-related fatigue, chronic fatigue syndrome, excessive daytime sleepiness associated with primary insomnia, and other uses not specified in the coverage criteria.

Common denial triggers: ADHD; bipolar disorder (including bipolar depression); cancer-related fatigue; chronic fatigue syndrome; excessive daytime sleepiness associated with primary insomnia
Requests lacking required diagnostic testing, specialist consultation (when required), or without documentation of generic trial for brand requests are at risk of denial
Claims submitted without covered diagnosis or procedure codes will be denied as not covered

Step Therapy

Generic-first requirement for brand products

When clinically appropriate, patients must try one Step 1 product (generic modafinil or generic armodafinil) prior to approval of brand Provigil or brand Nuvigil. Brand consideration requires documentation of the failed generic trial or documented intolerance/allergy to the generic formulation (e.g., attributable to inactive ingredients).

Step 1: generic modafinil or generic armodafinil trial required before brand Provigil/Nuvigil
Brand will be approved only if generic trial failed or prescriber documents formulation-based intolerance/allergy